Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: implications for immune-mediated therapy of EBV+ Hodgkin's disease.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Blood

• Publication date

  1997-03-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD.V89.6.1978PMID 9058719
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease.

  1996cited by this paper
• Analysis of major histocompatibility complex class I expression on Reed-Sternberg cells in relation to the cytotoxic T-cell response in Epstein-Barr virus-positive and -negative Hodgkin's disease.

  1996cited by this paper
• T–cell mediated rejection of gene–modified HIV–specific cytotoxic T lymphocytes in HIV–infected patients

  1996cited by this paper
• T cells from patients with Hodgkin's disease have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28.

  1996cited by this paper
• A comprehensive approach for typing the alleles of the HLA-B locus by automated sequencing.

  1995cited by this paper
• LMP-1 activates NF-kappa B by targeting the inhibitory molecule I kappa B alpha

  1995cited by this paper
• Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor.

  1995cited by this paper
• Nomenclature for Factors of the HLA System, 1995

  1995cited by this paper
• Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation.

  1995cited by this paper
• Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease.

  1995cited by this paper
• Inhibition of antigen processing by the internal repeat region of the Epstein–Barr virus nuclear antigen-1

  1995cited by this paper
• Alterations in T cell receptor and signal transduction molecules in melanoma patients.

  1995cited by this paper
• Nomenclature for factors of the HLA system, 1995.

  1995cited by this paper
• The treatment of Hodgkin's disease.

  1994cited by this paper
• Molecular diversity of the HLA-C locus in unrelated marrow transplantation.

  1994cited by this paper
• Absence of HLA class I expression by Reed-Sternberg cells.

  1994cited by this paper
• Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.

  1994cited by this paper
• Potential antigenic targets on Epstein-Barr virus-associated tumours and the host response.

  1994cited by this paper
• T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells

  1994cited by this paper
• Morphologic and immunophenotypic characterization of a cell line derived from liver tissue with epstein-barr virus associated post-transplant lymphoproliferative disease

  1994cited by this paper
• A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target

  1993cited by this paper
• EBV peptide epitope sensitization restores human cytotoxic T cell recognition of Burkitt's lymphoma cells. Evidence for a critical role for ICAM-2.

  1993cited by this paper
• Tumor Escape from Immune Response by Variation in HLA Expression and Other Mechanisms

  1993cited by this paper
• Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells

  1993cited by this paper
• Expression of Epstein-Barr virus latent gene products and related cellular activation and adhesion molecules in Hodgkin's disease and non-Hodgkin's lymphomas arising in patients without overt pre-existing immunodeficiency.

  1993cited by this paper
• Identification of human cancers deficient in antigen processing

  1993cited by this paper
• Hodgkin's disease: analysis of cell line data.

  1992cited by this paper
• Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice.

  1992cited by this paper
• Hodgkin's disease cell lines: a model for interleukin-1-independent accessory cell function.

  1992cited by this paper
• Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies

  1992cited by this paper
• Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones.

  1992cited by this paper
• Immune escape by Epstein-Barr virus (EBV) carrying Burkitt's lymphoma: in vitro reconstitution of sensitivity to EBV-specific cytotoxic T cells.

  1992cited by this paper
• Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure.

  1992cited by this paper
• Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease.

  1991cited by this paper
• Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease.

  1991cited by this paper
• Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man

  1991cited by this paper
• MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease.

  1991cited by this paper
• A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

  1991cited by this paper
• Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells.

  1991cited by this paper
• Expression of epstein‐barr virus‐encoded growth‐transformation‐associated proteins in lymphoproliferations of bone‐marrow transplant recipients

  1991cited by this paper
• Expression of Epstein-Barr virus nuclear antigens in anti-IgM-stimulated B cells following recombinant vaccinia infection and their recognition by human cytotoxic T cells.

  1991cited by this paper
• Detection of ebv gene expression in reed‐sternberg cells of Hodgkin's disease

  1990cited by this paper
• Human cytotoxic T-cell responses against Epstein-Barr virus nuclear antigens demonstrated by using recombinant vaccinia viruses.

  1990cited by this paper
• High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease.

  1990cited by this paper
• Suppression of class I human histocompatibility leukocyte antigen by c- myc is locus specific

  1989cited by this paper
• Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987.

  1989cited by this paper
• Variation in HLA expression on tumors: an escape from immune response.

  1989cited by this paper
• A survey of Epstein-Barr virus DNA in lymphoid tissue. Frequent detection in Hodgkin's disease.

  1989cited by this paper
• Characterization of Hodgkin's disease derived cell line HDLM-2.

  1989cited by this paper
• Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein- Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance

  1988cited by this paper
• Epidemiologic studies assessing the role of the Epstein-Barr virus in Hodgkin's disease.

  1987cited by this paper
• Epstein-Barr viral DNA in tissues of Hodgkin's disease.

  1987cited by this paper
• Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines.

  1987cited by this paper
• An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells.

  1985cited by this paper
• Tumor growth and evasion of immune destruction: UV-induced tumors as a model

  1985cited by this paper
• Target specificity and cell surface structures involved in the human cytolytic T lymphocyte response to endothelial cells.

  1985cited by this paper
• Depressed T cell proliferative responses in Hodgkin's disease: role of monocyte-mediated suppression via prostaglandins and hydrogen peroxide.

  1982cited by this paper
• Epstein-Barr virus antibody in childhood Hodgkin's disease.

  1982cited by this paper
• Presence of elevated antibody titres to Epstein-Barr virus before Hodgkin's disease.

  1981cited by this paper
• Letter: Mobility of medical manpower.

  1976cited by this paper
• The treatment of Hodgkin's disease.

  1966cited by this paper

• Targeting Driver Oncogenes and Other Public Neoantigens Using T Cell Receptor–Based Cellular Therapy

  2023cites this paper
• Cure of intravascular NK/T-cell lymphoma of the central nervous system by allogeneic hematopoietic cell transplantation

  2022cites this paper
• Induction of EBV latent membrane protein-2A (LMP2A)-specific T cells and construction of individualized TCR-engineered T cells for EBV-associated malignancies

  2021cites this paper
• Immunotherapy with the Vaccine Based On the Canine Neurotropic Virus (CIMT-54) For the Treatment of Cancer

  2019cites this paper
• Turning Up Antitumor Immunity Against Breast Cancer

  2018cites this paper
• This information is current as Carcinoma and Lymphoma Patients with EBV-Positive Nasopharyngeal Protein 2 Specificity in CTL Lines from Characterization of Latent Membrane

  2017cites this paper
• Th17 immune microenvironment in Epstein-Barr virus-negative Hodgkin lymphoma: implications for immunotherapy.

  2017cites this paper
• The dawn of vaccines for cancer prevention

  2017cites this paper
• EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas.

  2017cites this paper
• The Safety and Immunological Effects of rAd5-EBV-LMP2 Vaccine in Nasopharyngeal Carcinoma Patients: A Phase I Clinical Trial and Two-Year Follow-Up.

  2016cites this paper
• Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non‐Hodgkin lymphoma

  2016cites this paper
• Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target

  2015cites this paper
• Title Epstein Barr virus-associated lymphoproliferative diseases : thevirus as a therapeutic target

  2015cites this paper
• Enhanced antitumor effect of combining chemotherapy with Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes in mice with EBV-related non-Hodgkin's lymphoma.

  2015cites this paper
• Malignancies associated with epstein-barr virus: pathobiology, clinical features, and evolving treatments.

  2014cites this paper
• T lymphocyte responses effective in vitro vaccine designed to elicit EBV-specific CD4+ and CD8+ thaw cell lysates define an - Mature dendritic cells pulsed with freeze

  2013cites this paper
• for the adoptive Immunotherapy of EBV-associated malignancies Generating CTL against the subdominant Epstein-Barr virus LMP1 antigen

  2013cites this paper
• Survival in Hodgkin's Disease Effect of Epstein-Barr Virus Infection on Response to Chemotherapy and

  2013cites this paper
• Treatment of Epstein–Barr Virus Infections: Chemotherapy, Antiviral Therapy, and Immunotherapy

  2013cites this paper
• malignancies antigen for the adoptive immunotherapy of EBV-associated Generating CTLs against the subdominant Epstein-Barr virus LMP1

  2013cites this paper
• Epstein-Barr Virus-Associated Classical Hodgkin Lymphoma and Its Therapeutic Strategies

  2011cites this paper
• Lymphoma EBV-Positive Nasopharyngeal Carcinoma and Specificity in CTL Lines from Patients with Characterization of Latent Membrane Protein 2

  2011cites this paper
• Immunotherapy and vaccination after transplant: the present, the future.

  2010cites this paper
• Immunotherapy and vaccination after transplant: the present, the future.

  2010cites this paper
• Treatment of lymphoma with adoptively transferred T cells

  2009cites this paper
• This information is current as Peptidase II Involvement Tripeptidyl 1 MHC Class I Epitopes Requires Processing of Two Latent Membrane Protein

  2009cites this paper
• Processing of Two Latent Membrane Protein 1 MHC Class I Epitopes Requires Tripeptidyl Peptidase II Involvement1

  2009cites this paper
• New biologic and therapeutic insights in Hodgkin's lymphoma

  2009cites this paper
• Adoptive cellular immunotherapy for childhood malignancies

  2008cites this paper
• Immunotherapies for Hodgkin's lymphoma.

  2008cites this paper
• In vitro methods for generating highly purified EBV associated tumor antigen-specific T cells by using solid phase T cell selection system for immunotherapy.

  2007cites this paper
• Interferon-gamma expressing EBV LMP2A-specific T cells for cellular immunotherapy.

  2007cites this paper
• Contribution of the Epstein–Barr virus to the molecular pathogenesis of Hodgkin lymphoma

  2006cites this paper
• An Evidence-Based Approach to the Management of Hodgkin’s Lymphoma

  2006cites this paper
• Adoptive Immunotherapy for Hodgkin’s Lymphoma

  2006cites this paper
• Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma.

  2006cites this paper
• Adoptive T-Cell therapy as treatment for Epstein Barr virus-associated malignancies : strategies to enhance potential and broaden application

  2006cites this paper
• Adoptive Transfer of Epstein-Barr Virus-Specific Cytotoxic T-Lymphocytes for the Treatment of Angiocentric Lymphomas

  2006cites this paper
• Chapter 4 The Generation and Characterization of LMP 2-specific CTLs for Use As Adoptive Transfer From Patients with Relapsed EBV-Positive Hodgkin Disease

  2006cites this paper
• Carcinoma and Lymphoma Patients with EBV-Positive Nasopharyngeal Protein 2 Specificity in CTL Lines from Characterization of Latent Membrane Rooney and

  2005cites this paper
• Effects of Bcl-2 Levels on Fas Signaling-Induced Caspase-3 Activation: Molecular Genetic Tests of Computational Model Predictions1

  2005cites this paper
• Clinical trials in North America

  2005cites this paper
• Impact of latent Epstein-Barr virus infection on outcome in children and adolescents with Hodgkin's lymphoma.

  2005cites this paper
• Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance.

  2004cites this paper
• Epstein–Barr virus‐associated Hodgkin's lymphoma

  2004cites this paper
• Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus+ Hodgkin's Disease

  2004cites this paper
• Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts

  2004cites this paper
• The Generation and Characterization of LMP2-Specific CTLs for Use as Adoptive Transfer From Patients With Relapsed EBV-Positive Hodgkin Disease

  2004cites this paper
• Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.

  2004cites this paper
• Adoptive immunotherapy with allogeneic Epstein–Barr virus (EBV)‐specific cytotoxic T‐lymphocytes for recurrent, EBV‐positive Hodgkin disease

  2004cites this paper
• Vaccines in leukemia.

  2004cites this paper
• T cell-based therapies for EBV-associated malignancies

  2004cites this paper
• Immune dysfunction in classical Hodgkin lymphoma.

  2004cites this paper
• Immune responses against spontaneous tumors in a murine model for pancreatic adenocarcinoma

  2004cites this paper
• Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.

  2003cites this paper
• Adoptive T-Cell Therapy for Epstein-Barr Virus-Positive Hodgkin’s Disease

  2003cites this paper
• The B Subunit of Escherichia coli Heat-Labile Enterotoxin Enhances CD8+ Cytotoxic-T-Lymphocyte Killing of Epstein-Barr Virus-Infected Cell Lines

  2003cites this paper
• Tissue inhibitor of metalloproteinases 1 is an autocrine and paracrine survival factor, with additional immune-regulatory functions, expressed by Hodgkin/Reed-Sternberg cells.

  2002cites this paper
• Frequent expression of the Epstein–Barr virus (EBV)‐induced gene, EBI3, an IL‐12 p40‐related cytokine, in Hodgkin and Reed–Sternberg cells

  2002cites this paper
• Lack of evidence for an association of Epstein–Barr virus infection with breast carcinoma

  2002cites this paper
• Generating CTL against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive Immunotherapy of EBV-associated malignancies Running title: Generation of LMP1-specific CTL Scientific Section Heading: Immunotherapy

  2002cites this paper
• Expression of the signal transduction molecule ζ in peripheral and tumour‐associated lymphocytes in Hodgkin's disease in relation to the Epstein–Barr virus status of the tumour cells

  2002cites this paper
• Achievements and Perspectives

  2002cites this paper
• A defective, rearranged Epstein-Barr virus genome in EBER-negative and EBER-positive Hodgkin's disease.

  2002cites this paper
• Identification and prevalence of CD8+ T‐cell responses directed against Epstein‐Barr virus‐encoded latent membrane protein 1 and latent membrane protein 2

  2002cites this paper
• Epstein-Barr virus vaccine: a cytotoxic T-cell-based approach

  2002cites this paper
• New targets for the treatment of advanced non-small cell lung cancer.

  2002cites this paper
• Viruses and lymphomas.

  2002cites this paper
• Safety of allogeneic Epstein–Barr virus (EBV)‐specific cytotoxic T lymphocytes for patients with refractory EBV‐related lymphoma

  2002cites this paper
• Epstein‐Barr virus infection and human malignancies

  2001influential citation
• Expression of cytokine and chemokine genes in Epstein–Barr virus‐associated nasopharyngeal carcinoma: comparison with Hodgkin's disease

  2001cites this paper
• Epstein-Barr virus infection and human malignancies.

  2001cites this paper
• Immunotherapeutic strategies for EBV-associated malignancies.

  2001cites this paper
• Epstein-Barr Virus Latent Membrane Protein 1 (LMP-1) in Hodgkin's Lymphoma Patients in Turkey.

  2001cites this paper
• Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: A potential treatment strategy for Epstein‐Barr virus–positive Hodgkin's lymphoma

  2001cites this paper
• Adoptiver Transfer von tumorreaktiven T-Zellen

  2001cites this paper
• Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide.

  2001cites this paper
• Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.

  2001cites this paper
• Editorial comment on detection of Epstein-Barr virus DNA in peripheral blood of paediatric patients with Hodgkin's disease by real-time polymerase chain reaction by Wagner and colleagues.

  2001cites this paper
• Assessment of the prognostic impact of the Epstein–Barr virus-encoded latent membrane protein-1 expression in Hodgkin's disease

  2001cites this paper
• The Generation of Both T Killer and Th Cell Clones Specific for the Tumor-Associated Antigen HER2 Using Retrovirally Transduced Dendritic Cells1

  2001cites this paper
• Prostate Cancer Immunotherapy Development in Prostate Specific Antigen Transgenic Mice

  2001cites this paper
• Transduced Dendritic Cells Antigen HER2 Using Retrovirally Clones Specific for the Tumor-Associated The Generation of Both T Killer and Th Cell

  2001cites this paper
• ADENOVIRA LGEN ETRANSFE RINT ODENDRITI CCELL SEFFICIENTLY AMPLIFIE STH EIMMUN ERESPONS ET OLMP2 AANTIGEN : APOTENTIAL TREATMEN TSTRATEG YFO REPSTEIN-BAR RVIRUS-POSITIV EHODGKIN'S LYMPHOMA

  2001cites this paper
• [Hodgkin's disease: biology can help the physician towards new prognostic factors and new therapeutic approaches].

  2001cites this paper
• Inhibition of Epstein–Barr virus (EBV)‐specific CD8+ cytotoxic T lymphocyte (CTL) activity by soluble HLA class I in vitro

  2000cites this paper
• Adoptive immunotherapy with donor lymphocyte infusionsafter allogeneic HPC transplantation

  2000cites this paper
• Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses.

  2000cites this paper
• Hodgkin's disease and the Epstein-Barr virus

  2000cites this paper
• Strategies for immunotherapy of cancer.

  2000cites this paper
• Progenitor Cells Hemopoietic + Derived from CD34 Retrovirally Transduced Dendritic Cells the Tumor-Associated Antigen HER2 Using Generation of Tumor-Reactive CTL Against

  2000cites this paper
• Epstein-Barr virus and hodgkin’s disease

  2000cites this paper
• Molecular single-cell analysis of the clonal relationship of small Epstein-Barr virus-infected cells and Epstein-Barr virus-harboring Hodgkin and Reed/Sternberg cells in Hodgkin disease.

  2000cites this paper
• Generation of Tumor-Reactive CTL Against the Tumor-Associated Antigen HER2 Using Retrovirally Transduced Dendritic Cells Derived from CD34+ Hemopoietic Progenitor Cells1

  2000cites this paper
• Expression of gene MAGE-A4 in Reed-Sternberg cells.

  2000cites this paper
• Production monitoring and purification of EBV encoded latent membrane protein 1 expressed and secreted by recombinant baculovirus infected insect cells.

  2000cites this paper
• immunotherapeutic strategies targeted at EBV positive patients with Hodgkin’s disease

  2000cites this paper
• Introduction: The Graft-Versus-Leukemia Effect

  2000cites this paper
• Parameters involved in the recognition of fresh human leukemic blasts by tumor-specific cytolytic T cell clones: a model study.

  2000cites this paper
• Application of the ELISPOT assay to the characterization of CD8(+) responses to Epstein-Barr virus antigens.

  2000cites this paper